z-logo
Premium
Allergic Conjunctivitis Renders CD4 + T Cells Resistant to T Regulatory Cells and Exacerbates Corneal Allograft Rejection
Author(s) -
Reyes N. J.,
Chen P. W.,
Niederkorn J. Y.
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12198
Subject(s) - immunology , immune privilege , medicine , cytotoxic t cell , immune system , allergic conjunctivitis , effector , t cell , ctl* , allergy , biology , cd8 , biochemistry , in vitro
Allergic diseases rob corneal allografts of immune privilege and increase immune rejection. Corneal allograft rejection in BALB/c allergic hosts was analyzed using a short ragweed (SWR) pollen model of allergic conjunctivitis. Allergic conjunctivitis did not induce exaggerated T‐cell responses to donor C57BL/6 (B6) alloantigens or stimulate cytotoxic T lymphocyte (CTL) responses. Allergic conjunctivitis did affect T regulatory cells (Tregs) that support graft survival. Exogenous IL‐4, but not IL‐5 or IL‐13, prevented Treg suppression of CD4 + effector T cells isolated from naïve mice. However, mice with allergic conjunctivitis developed Tregs that suppressed CD4 + effector T‐cell proliferation. In addition, IL‐4 did not inhibit Treg suppression of IL‐4Rα −/− CD4 + T‐cell responses, suggesting that IL‐4 rendered effector T cells resistant to Tregs. SRW‐sensitized IL‐4Rα −/− mice displayed the same 50% graft survival as nonallergic WT mice, that was significantly less than the 100% rejection that occurred in allergic WT hosts, supporting the role of IL‐4 in the abrogation of immune privilege. Moreover, exacerbation of corneal allograft rejection in allergic mice was reversed by administering anti‐IL‐4 antibody. Thus, allergy‐induced exacerbation of corneal graft rejection is due to the production of IL‐4, which renders effector T cells resistant to Treg suppression of alloimmune responses.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here